226 related articles for article (PubMed ID: 8221655)
1. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
Shaw GL; Gazdar AF; Phelps R; Linnoila RI; Ihde DC; Johnson BE; Oie HK; Pass HI; Steinberg SM; Ghosh BC
Cancer Res; 1993 Nov; 53(21):5181-7. PubMed ID: 8221655
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.
Cortazar P; Gazdar AF; Woods E; Russell E; Steinberg SM; Williams J; Ihde DC; Johnson BE
Clin Cancer Res; 1997 May; 3(5):741-7. PubMed ID: 9815744
[TBL] [Abstract][Full Text] [Related]
3. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
[TBL] [Abstract][Full Text] [Related]
4. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients.
Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Imamura F; Minamikawa K; Takano T; Kobayashi H
Lung Cancer; 2010 Jun; 68(3):472-7. PubMed ID: 19660825
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST).
Kawamura M; Gika M; Abiko T; Inoue Y; Oyama T; Izumi Y; Kobayashi H; Kobayashi K
Cancer Chemother Pharmacol; 2007 Mar; 59(4):507-13. PubMed ID: 16896928
[TBL] [Abstract][Full Text] [Related]
7. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
9. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
12. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
Moon YW; Choi SH; Kim YT; Sohn JH; Chang J; Kim SK; Park MS; Chung KY; Lee HJ; Kim JH
Cancer; 2007 May; 109(9):1829-35. PubMed ID: 17366594
[TBL] [Abstract][Full Text] [Related]
13. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
Waller D; Peake MD; Stephens RJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG
Eur J Cardiothorac Surg; 2004 Jul; 26(1):173-82. PubMed ID: 15200998
[TBL] [Abstract][Full Text] [Related]
15. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
Dunant A; Pignon JP; Le Chevalier T
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5017s-5021s. PubMed ID: 16000606
[TBL] [Abstract][Full Text] [Related]
17. Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines.
Gazdar AF; Kadoyama C; Venzon D; Park JG; Tsai CM; Linnoila RI; Mulshine JL; Ihde DC; Giaccone G
J Natl Cancer Inst Monogr; 1992; (13):191-6. PubMed ID: 1327032
[TBL] [Abstract][Full Text] [Related]
18. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
